Remdesivir Intermediate CAS 1354823-36-1 COVID-19

Short Description:

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester

CAS: 1354823-36-1 

Intermediate of Remdesivir (CAS 1809249-37-3) for the treatment of COVID-19

Contact: Dr. Alvin Huang   

Mobile/Wechat/WhatsApp: +86-15026746401   

E-Mail: alvin@ruifuchem.com 


Product Detail

Related Products

Product Tags

Description:

1354823-36-1 - Chemical Properties:

Chemical Name N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester
Synonyms Remdesivir Intermediate; Remdesivir Side Chain; Remdesivir p-NitroPhenoxy L-Alanine Impurity; Remdesivir Impurity 4; Remdesivir-002; (S)-2-Ethylbutyl 2-(((S)-(4-nitrophenoxy)(phenoxy)-phosphoryl)-amino)propanoate; Remdesivir-002-SS
CAS Number 1354823-36-1
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C21H27N2O7P
Molecular Weight 450.42
Density 1.241±0.06 g/cm3
COA & MSDS Available
Place of Origin  China
Product Categories Remdesivir Intermediate
Brand Ruifu Chemical

1354823-36-1 - Specifications:

Item Specifications
Appearance White to Almost White Powder 
Identification IR, HPLC
Loss on Drying ≤1.00%
Single Impurity ≤0.50%
Heavy Metals ≤20ppm
Purity ≥98.0% 
Test Standard Enterprise Standard
Usage Intermediate of Remdesivir (CAS 1809249-37-3); COVID-19

1354823-36-1 - Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture.

Advantages:

1

1354823-36-1 - FAQ:

www.ruifuchem.com

1354823-36-1 - Application:

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester (CAS 1354823-36-1, also known as Remdesivir Impurity 4) is a phosphoramidate sidechain typically used for the preparation of Remdesivir (CAS 1809249-37-3, GS-5734), which is a novel antiviral investigational drug originally for the treatment of Ebola virus disease and Marburg virus infections and has subsequently also been found to show antiviral activity against coronaviruses (e.g. SARS-Cov-2/Covid-19). During the outbreak of the new Coronavirus Disease 2019 (COVID-19), Remdesivir (CAS 1809249-37-3) is one of the COVID-19 related research products. Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID-19 pandemic, Remdesivir was approved or authorized for emergency use to treat COVID-19 in around 50 countries. Updated guidelines from the World Health Organization in November 2020 include a conditional recommendation against the use of Remdesivir for the treatment of COVID-19.

  • Write your message here and send it to us